John S Bradley1, Tinatin Antadze2, Borislav Ninov3, Mohammed S Tayob4, Natasha Broyde5, Joan R Butterton5, Margaret Z Chou5, Carisa S De Anda5, Jason Y Kim5, Pamela S Sears5. 1. From the Merck Research Laboratories, Rady Children's Hospital/UCSD, San Diego, CA. 2. Merck Research Laboratories, LTD M. Iashvili Children's Central Hospital, Tbilisi, Georgia. 3. Merck Research Laboratories, UMHAT Dr. Georgi Stranski EAD, Pleven, Bulgaria. 4. Merck Research Laboratories, Mzansi Ethical Research Centre, Middelburg, South Africa. 5. Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ.
Abstract
BACKGROUND:Tedizolid phosphate is an oxazolidinone prodrug approved in 2014 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs); however, efficacy has not previously been evaluated in children. This study compared the safety and efficacy of tedizolid (administered as tedizolid phosphate) with active antibacterial comparators for the treatment of ABSSSIs in adolescents. METHODS: This was a randomized, assessor-blind, global phase 3 study of tedizolid versus active comparators for the treatment of Gram-positive ABSSSIs in adolescents (12 to <18 years of age; NCT02276482). Enrolled participants were stratified by region and randomized 3:1 to receive tedizolid phosphate 200 mg (oral and/or intravenous) once daily for 6 days or active comparator, selected by investigator from an allowed list per local standard of care, for 10 days. The primary endpoint was safety; blinded investigator's assessment of clinical success at the test-of-cure visit (18-25 days after the first dose) was a secondary efficacy endpoint. Statistical comparisons between treatment groups were not performed. RESULTS: Of the 121 participants enrolled, 120 were treated (tedizolid, n = 91; comparator, n = 29). Treatment-emergent adverse events were balanced between treatment groups (tedizolid, 14.3%; comparator, 10.3%). Overall, 3 participants (3.3%) in the tedizolid group and 1 (3.4%) in the comparator group experienced a single drug-related TEAE. Clinical success rates were high in both treatment groups: 96.7% and 93.1% at the test-of-cure visit for the tedizolid and comparator groups, respectively. CONCLUSIONS:Tedizolid demonstrated safety and efficacy similar to comparators for the treatment of ABSSSIs in adolescents.
RCT Entities:
BACKGROUND:Tedizolid phosphate is an oxazolidinone prodrug approved in 2014 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs); however, efficacy has not previously been evaluated in children. This study compared the safety and efficacy of tedizolid (administered as tedizolid phosphate) with active antibacterial comparators for the treatment of ABSSSIs in adolescents. METHODS: This was a randomized, assessor-blind, global phase 3 study of tedizolid versus active comparators for the treatment of Gram-positive ABSSSIs in adolescents (12 to <18 years of age; NCT02276482). Enrolled participants were stratified by region and randomized 3:1 to receive tedizolid phosphate 200 mg (oral and/or intravenous) once daily for 6 days or active comparator, selected by investigator from an allowed list per local standard of care, for 10 days. The primary endpoint was safety; blinded investigator's assessment of clinical success at the test-of-cure visit (18-25 days after the first dose) was a secondary efficacy endpoint. Statistical comparisons between treatment groups were not performed. RESULTS: Of the 121 participants enrolled, 120 were treated (tedizolid, n = 91; comparator, n = 29). Treatment-emergent adverse events were balanced between treatment groups (tedizolid, 14.3%; comparator, 10.3%). Overall, 3 participants (3.3%) in the tedizolid group and 1 (3.4%) in the comparator group experienced a single drug-related TEAE. Clinical success rates were high in both treatment groups: 96.7% and 93.1% at the test-of-cure visit for the tedizolid and comparator groups, respectively. CONCLUSIONS:Tedizolid demonstrated safety and efficacy similar to comparators for the treatment of ABSSSIs in adolescents.
Authors: Dan Li; Philip E Sabato; Benjamin Guiastrennec; Aziz Ouerdani; Hwa-Ping Feng; Vincent Duval; Carisa S De Anda; Pamela S Sears; Margaret Z Chou; Catherine Hardalo; Natalya Broyde; Matthew L Rizk Journal: Antimicrob Agents Chemother Date: 2021-09-13 Impact factor: 5.191